EirGenix (TWO:6589) — Market Cap & Net Worth
Market Cap & Net Worth: EirGenix (6589)
EirGenix (TWO:6589) has a market capitalization of $632.48 Million (NT$20.08 Billion) as of June 16, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #11246 globally and #415 in its home market, demonstrating a 7.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EirGenix's stock price NT$66.40 by its total outstanding shares 302337984 (302.34 Million). Review 6589 total debt and obligations to assess the company's total debt and financial obligations.
EirGenix Market Cap History: 2016 to 2025
EirGenix's market capitalization history from 2016 to 2025. Data shows growth from $336.33 Million to $632.48 Million (5.61% CAGR).
EirGenix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EirGenix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.68x
EirGenix's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $222.26 Million | $297.87 Million | -$174.85 Million | 0.75x | N/A |
| 2018 | $273.81 Million | $282.21 Million | -$367.79 Million | 0.97x | N/A |
| 2019 | $242.45 Million | $476.08 Million | -$860.92 Million | 0.51x | N/A |
| 2020 | $426.06 Million | $1.07 Billion | -$1.04 Billion | 0.40x | N/A |
| 2021 | $1.06 Billion | $1.70 Billion | -$42.58 Million | 0.63x | N/A |
| 2022 | $1.17 Billion | $1.48 Billion | -$115.54 Million | 0.79x | N/A |
| 2023 | $957.29 Million | $1.02 Billion | -$915.21 Million | 0.94x | N/A |
| 2024 | $685.82 Million | $1.01 Billion | -$698.34 Million | 0.68x | N/A |
Competitor Companies of 6589 by Market Capitalization
Companies near EirGenix in the global market cap rankings as of June 16, 2026.
Key companies related to EirGenix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
EirGenix Historical Marketcap From 2016 to 2025
Between 2016 and today, EirGenix's market cap moved from $336.33 Million to $ 632.48 Million, with a yearly change of 5.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | NT$632.48 Million | -7.78% |
| 2024 | NT$685.82 Million | -28.36% |
| 2023 | NT$957.29 Million | -18.29% |
| 2022 | NT$1.17 Billion | +10.31% |
| 2021 | NT$1.06 Billion | +149.28% |
| 2020 | NT$426.06 Million | +75.73% |
| 2019 | NT$242.45 Million | -11.45% |
| 2018 | NT$273.81 Million | +23.19% |
| 2017 | NT$222.26 Million | -33.92% |
| 2016 | NT$336.33 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of EirGenix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $632.48 Million USD |
| MoneyControl | $632.48 Million USD |
| MarketWatch | $632.48 Million USD |
| marketcap.company | $632.48 Million USD |
| Reuters | $632.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more